A Study of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older (60 to 79 Years Inclusive) Participants (V330-001)

Launched by MERCK SHARP & DOHME LLC · Oct 3, 2024

Keywords

ClinConnect Summary

This clinical trial, called V330-001, is exploring a new vaccine known as V330 to see if it is safe and how well it helps the body produce antibodies. Antibodies are proteins that help fight off infections. The study is open to healthy individuals aged 18 to 49 and those aged 60 to 79, as they want to understand how different age groups respond to the vaccine.

To participate, you need to be in good health and meet the age criteria mentioned above. However, individuals with a history of heart inflammation or cancer will not be eligible. If you join the study, you can expect to receive the vaccine and be monitored for your health and immune response. This research is important as it could lead to new ways to protect people from illnesses by enhancing the immune system.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• The key inclusion criteria include but are not limited to the following:
• • Is in good health prior to randomization
• • Is an individual from 18 to 49 years of age inclusive or from 60 to 79 years of age inclusive
• Exclusion Criteria:
• The key exclusion criteria include but are not limited to the following:
• • Has a history of myocarditis, pericarditis, and/or myopericarditis
• • Has a history of cancer